Table 5 The SNPs associated with the outcomes of unrelated CBT in recipient genotype analysis.
SNP | Gene | Chromosome position (bp) | Source | Outcome /status | Recipient genotype frequency (%) | Test | p-value | OR (95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|---|
rs107822 | RING1 | Chr6: 33,175,575 | rs107822 | Survival | CC | CT | TT | Dominant | 0.017 | 4.909 (1.229–19.606) |
Yes | 5 (100.0) | 22 (88.0) | 22 (64.7) | |||||||
No | 0 (0) | 3 (12.0) | 12 (35.3) | |||||||
rs2070120 | HLA-DOB | Chr6: 32,780,914 | rs2071479 | Survival | AA | AG | GG | Dominant | 0.027 | 0.178 (0.040–0.783) |
Yes | 0 (0) | 4 (50.0) | 45 (81.8) | |||||||
No | 1 (100.0) | 4 (50.0) | 10 (18.2) | |||||||
rs17220087 | HLA-DOB | Chr6: 32,781,076 | rs2071479 | Survival | AA | AC | CC | Dominant | 0.027 | 0.178 (0.040–0.783) |
Yes | 0 (0) | 4 (50.0) | 45 (81.8) | |||||||
No | 1 (100.0) | 4 (50.0) | 10 (18.2) | |||||||
rs17213693 | HLA-DOB | Chr6: 32,781,121 | rs2071479 | Survival | CC | CG | GG | Dominant | 0.027 | 0.178 (0.040–0.783) |
Yes | 0 (0) | 4 (50.0) | 45 (81.8) | |||||||
No | 1 (100.0) | 4 (50.0) | 10 (18.2) | |||||||
rs9281491 | HCP5 | Chr6: 31,435,815: | rs2244546 | GVHD = 3 & 4 | AA | A- | – | Recessive | 0.013 | 10.889 (1.729–68.576) |
31,435,816 | Yes | 4 (66.7) | 6 (21.4) | 3 (10.0) | ||||||
No | 2 (33.3) | 22 (78.6) | 27 (90.0) | |||||||
rs4713466 | HCP5 | Chr6: 31,435,869 | rs2244546 | GVHD = 3 & 4 | CC | CT | TT | Dominant | 0.013 | 0.092(0.015–0.578) |
Yes | 12 (27.9) | 1 (5.9) | 0 (0) | |||||||
No | 31 (72.1) | 16 (94.1) | 4 (100.0) | |||||||
